A phase 2 study of PTG-007 in patients with progressive relapsing multiple sclerosis
Latest Information Update: 19 Sep 2024
At a glance
- Drugs PTG 007 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2024 New trial record
- 16 Sep 2024 According to a PolTREG media release , company is set to launch this study in Q4 2024